COSCIENS Biopharma Inc. Reports Q1 2026 Results

• Q1 2026 Financial Performance: Reported net income of $10.8 million, reversing a $3.7 million loss from Q1 2025. This profit is primarily driven by a one-time accounting gain of $10.9 million from the deconsolidation of German subsidiaries (Aeterna Zentaris GmbH and Zentaris IVF GmbH).
• Operational Reality: Net loss from continuing operations was $0.2 million ($0.06 per share), indicating core business remains unprofitable. Total revenue increased slightly to $1.9 million from $1.4 million in Q1 2025.
• Program Discontinuation: The AvenActive program (inflammation management) has been discontinued following Phase 2a results that were not statistically significant, despite biomarker changes at higher doses.
• German Subsidiary Insolvency: German subsidiaries filed for insolvency on March 23, 2026. COSCIENS ceased funding them and derecognized their assets/liabilities as of March 27, 2026. This removes an $11.0 million unfunded pension liability from future statements but eliminates rights to the Macrilen® product in those jurisdictions.
• Capital Structure & Reporting: Company plans a share reorganization (consolidation and split) to reduce record holders below 300, enabling suspension of SEC reporting obligations (Form 15). Shareholder meeting scheduled for June 17, 2026. Small shareholders (<150 pre-consolidation shares) will be cashed out at $1.60 per share.
• Cash Position: Cash and equivalents dropped to $5.0 million as of March 31, 2026, down from $7.3 million in December 2025 and $8.5 million in September 2025.

• Accounting Gain vs. Operational Loss: The headline net income is misleading; the company remains operationally loss-making ($0.2M). The profit is a balance sheet cleanup exercise, not cash generation. This does not materially improve liquidity or long-term viability without external capital.
• Cash Burn Risk: Cash decreased by $2.3 million in Q1 2026 despite reduced operating expenses ($1.5M vs $3.0M). At this burn rate, the remaining $5.0 million cash runway is approximately 6 months or less, creating an imminent need for capital raising which could dilute shareholders.
• Pipeline Erosion: Discontinuing AvenActive and surrendering Macrilen rights (via German insolvency) removes the company's primary growth narratives. The active ingredients business remains the only revenue driver but is not sufficient to support a biopharma valuation without significant scaling.
• Regulatory Status Change: Suspending SEC reporting obligations reduces transparency and liquidity, likely depressing stock price due to reduced analyst coverage and institutional interest.
• Shareholder Impact: The share consolidation/split plan effectively squeezes out minority shareholders holding fewer than 150 shares, which may be viewed negatively by retail investors.

• Business Model: COSCIENS develops natural plant-based active ingredients (beta glucan, avenanthramides) and commercializes pharmaceutical products (Macrilen®).
• Flagship Project: Macrilen® (macimorelin), an FDA/EMA-approved oral diagnostic test for Adult Growth Hormone Deficiency. However, rights to this product are being surrendered due to German subsidiary insolvency.
• Secondary Projects: AvenActive (inflammation) program discontinued; PGX Technology (biocomposites) seeking partners; Active Ingredients business remains the core revenue generator.